| Revenue growth | 62% YoY for FY26; 58% for Q4FY26. |
|---|---|
| Margins | EBITDA margin expanded from 24.8% to 30.1% YoY. |
| Demand visibility | Targeting USD 630mn+ gross share from upcoming 105 ANDA products. |
| Management confidence | Strong visibility for regulated business growth via robust pipeline. |
Growth
Total Income grew 62% to ₹664 cr; EBITDA rose 96% to ₹199.6 cr; PAT surged 108% to ₹121.5 cr.
Outlook
Launching 30 ANDAs (USD 630mn+ target share); acquiring Zoraya (51%) and Apnar (balance 25%); greenfield API expansion to 169 MTPA.
Risks
Subject to drug shortages, regulatory fluctuations, international competition, and potential cost overruns on contracts.
Earnings Call filed with NSE, NSE: SENORES. Summary written with AI assistance from the document.
Senores Pharmaceuticals Ltd: key numbers
- Share price
- ₹1,355.20
- Market cap
- ₹6,241 Cr
- Revenue (annual)
- ₹632.6 Cr
- Net profit (annual)
- ₹115.4 Cr
- P/E (TTM)
- 49.4×Sector 50.4×
- Promoter holding
- 45.82%+0.00% QoQ
- FII holding
- 6.62%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Senores Pharmaceuticals Ltd
All →Senores Pharmaceuticals Annual General Meeting
Senores Pharmaceuticals held its 9th Annual General Meeting on September 25, 2026. Shareholders approved financial statements, director appointments, and the new Employee Stock Option Scheme 2026.
Senores Pharmaceuticals Price Movement Clarification
Senores Pharmaceuticals informed exchanges there is no undisclosed or price-sensitive information behind the volume spike. The company affirmed compliance with SEBI LODR disclosure obligations.
Senores Pharmaceuticals Other Announcement
Senores Pharmaceuticals Ltd submitted its shareholding pattern for the quarter ended 31 March 2026, in compliance with SEBI regulation 31(1)(b).
Senores Pharmaceuticals Business Update
Senores Pharma's subsidiary Apnar Pharma completed a USFDA inspection at its Vadodara facility with no GMP observations. Only one minor procedural finding was noted.
Senores Pharmaceuticals Annual Report
Senores Pharmaceuticals issued a corrigendum to its FY 2025-26 Annual Report to rectify typographical errors in the narrative and Director's Report sections. The original report remains valid.
Senores Pharmaceuticals Annual General Meeting
Senores Pharmaceuticals Ltd submitted its Annual Report for FY 2025-26 and notice for its 9th Annual General Meeting scheduled for September 25, 2026.